



Dr. Jörg Knäblein is currently heading the Microbiological Chemistry department at Schering AG in Berlin, after he was working for Schering's biotech subsidiary Berlex Biosciences in San Francisco and for Hoechst in New Jersey and in the UK.

His strong interest in biotechnology was laid already at a special highschool with focus on LifeSciences and then extended during his military services as an officer for ABC (atomic, biological, chemical) defense. He holds two diploma, one in *biotechnology* from *The Society of Biotechnology Research* (GBF) and another in *biochemistry* from *Max-Planck-Institute for Biochemistry*. Here, he also received his

PhD (*magna cum laude*) in one of the world's most recognized research groups with Professor Robert Huber (Nobel Prize laureate 1988).

After winning the McKinsey Business Plan contest, Dr. Knäblein founded a biotech company together with Professor Huber, before he took on the opportunity to work for the HighTech consultancy firm – focusing on the LifeScience business of global players. As an interim manager, he helped establishing the biggest eucalyptus oil plantation in Australia, 'Banalaster Eucalyptusoil Plantation' at Armidale, NSW, where he performed corporate communication, steered public relations as well as developed systems for ecological parasite eradication.

He is author of several books, and book chapters (including the outstanding reference "Encyclopedia of Molecular Cell Biology and Molecular Medicine", selected by ten Nobel Prize laureates!) and numerous publications in peer-reviewed journals, as well as a number of patents. Dr. Knäblein won several awards and honours, including McKinsey Award "Winner of the First Business Plan Contest", the "German Award from Government and Ministry of Science", and two "Scientific Awards" from the European Community and from the Max-Planck-Society.

Due to this distinguished career, and also as chairman and organizer of several international pharmaceutical conferences, he enjoys immense credibility within the LifeScience community and was therefore elected e.g. as "Executive Board Member and Scientific Advisor to the *European Association of Pharmaceutical Biotechnology*" (EAPB) (and also as its designated President), and to the "Editorial Board of the *European Journal of Pharmaceutics and Biopharmaceutics*" (EJPB), and the "Advisory Board of the *Drug Delivery Partnership*". In this context, he co-founded the "PharmaManagementNetwork", bringing together business leaders from LifeScience and the entire pharma world in order to discuss current industry trends and generate commercial opportunities.

Dr. Knäblein also founded the consultancy "*Global Pharma Specialists*" (GPS) and established the powerful biotechnology hub www.get-gps.net, which represents a global competence network of the most knowledgeable experts from academia and pharmaceutical industry. The portal is like a center of excellence where the world's top scientists and most influential business leaders divulge their first-hand expertise, discuss modern (bio)technology trends, and develop strategies to shape the pharmaceutical future. GPS also serves as an educational network to create a new generation of scientists and entrepreneurs, enabling business development and facilitating start-ups.

As a dynamic international scientist and businessman, Dr. Knäblein served as consultant for global players, among them Baxter, Hoechst and Elan Pharmaceuticals focusing on fast-track product development, time-to-market reduction and implementation of industry best practices (like e.g. GMP/GLP or QA/QC/QM). In addition, he is serving as advisor to international clients and institutions, e.g. the Iranian, Taiwan and Australian governments, where he is helping setting strategic directions for national biotech opportunities.

Dr. Knäblein is a charismatic speaker, who gives lectures and presentations on different biomedical, biotechnology and pharmaceutical conferences, ranging from stem cells & gene therapy, bio- & business-ethics, bioavailability & drug delivery formulations, over expression systems & plant biotechnology to GMP manufacturing & fast-track approval of drugs – “from transcription to prescription”. He was therefore also offered a lecturing position as Professor at the famous Charité university and hospital. From Silicon Valley to Bay Area, from Prague to London, and from Australia to Iranian Government, Dr. Knäblein’s advice offers cutting edge information and powerful new ideas for creative minds shaping the biotechnological and business landscape of the 21st century.